NCT07222410Recruiting
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
Closed Loop Oxygen Control in COPD Patients Treated With Nasal High Flow in the Hospital
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
The trial aims to evaluate whether the Airvo 3 device in OptiO2 mode can maintain patients' SpO2 levels within the target range better than manual oxygen titration in hospitalized COPD patients with hypoxemia/respiratory distress.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 23 Oct 2025
- Start date
- 7 Jan 2026
- Primary completion date
- Nov 2027
- Lead sponsor
- Fisher and Paykel Healthcare
- Diseases
- COPD
- NCT number
- NCT07222410
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 7 Jan 2026 to the primary completion date, Nov 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving Non Invasive Ventilation (NIV) or indicated for NIV as per European Respiratory Society /American Thoracic Society guidelines
- Patient receiving end of life care
Other illness
- Nasal or facial conditions precluding use of nasal high flow
- Cognitive impairment or impaired consciousness precluding informed consent
- Any other condition which, at the investigator's discretion, is believed to present a safety risk to the patient if included
- The presence of any active comorbidities that affect the patient's condition importantly in the next 30 days, as assessed by the investigator
Other
- Hemodynamic instability (systolic blood pressure \<90mmHg or requirement for vasopressor or inotropic support)
- Pregnancy or breastfeeding
- Unsuitable for adhesive finger pulse oximetry, as assessed by the investigator
- Has already participated in this clinical trial
Who the study is looking for
- Has cognitive ability to provide informed consent
- Aged 22 years or older
- Hospitalized with hypoxemia/respiratory distress
- Diagnosis of COPD
- Candidate for/currently prescribed nasal high flow (flow rate of at least 25 L/min) with supplemental oxygen, as assessed by the investigator
- Expected duration of oxygen and nasal high flow therapy \>24 hours (not necessarily continuous)
Age in the registry: 22 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
| Central Iowa Hospital Corp - UnityPoint Health Coordinator of this site? Confirm its status | Des Moines | United States | Recruiting |
| Icahn School of Medicine at Mount Sinai Coordinator of this site? Confirm its status | New York | United States | Recruiting |
| Temple University Hospital Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.